[go: up one dir, main page]

EE04141B1 - 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga - Google Patents

5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga

Info

Publication number
EE04141B1
EE04141B1 EEP200000141A EEP200000141A EE04141B1 EE 04141 B1 EE04141 B1 EE 04141B1 EE P200000141 A EEP200000141 A EE P200000141A EE P200000141 A EEP200000141 A EE P200000141A EE 04141 B1 EE04141 B1 EE 04141B1
Authority
EE
Estonia
Prior art keywords
combination
reuptake inhibitor
partial agonist
ht1b antagonist
ht1b
Prior art date
Application number
EEP200000141A
Other languages
English (en)
Estonian (et)
Inventor
Berg Stefan
Ross Svante
Thorberg Seth-Olov
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200000141A publication Critical patent/EE200000141A/xx
Publication of EE04141B1 publication Critical patent/EE04141B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
EEP200000141A 1997-09-18 1998-09-09 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga EE04141B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (2)

Publication Number Publication Date
EE200000141A EE200000141A (et) 2001-02-15
EE04141B1 true EE04141B1 (et) 2003-10-15

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000141A EE04141B1 (et) 1997-09-18 1998-09-09 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga

Country Status (29)

Country Link
US (1) US6159971A (xx)
EP (1) EP1014985B1 (xx)
JP (1) JP2001516718A (xx)
KR (1) KR20010024076A (xx)
CN (1) CN1195519C (xx)
AR (1) AR015448A1 (xx)
AT (1) ATE240733T1 (xx)
AU (1) AU752722B2 (xx)
BR (1) BR9812088A (xx)
CA (1) CA2302382A1 (xx)
DE (1) DE69814882T2 (xx)
DK (1) DK1014985T3 (xx)
EE (1) EE04141B1 (xx)
ES (1) ES2200370T3 (xx)
HU (1) HUP0200602A3 (xx)
IL (1) IL134776A0 (xx)
IS (1) IS5406A (xx)
MY (1) MY116280A (xx)
NO (1) NO20001399L (xx)
NZ (1) NZ503171A (xx)
PL (1) PL339371A1 (xx)
PT (1) PT1014985E (xx)
RU (1) RU2214824C2 (xx)
SE (1) SE9703375D0 (xx)
SK (1) SK2852000A3 (xx)
TR (1) TR200000727T2 (xx)
TW (1) TW589183B (xx)
WO (1) WO1999013877A1 (xx)
ZA (1) ZA987817B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
MX2009001551A (es) 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
DE69814882D1 (de) 2003-06-26
PT1014985E (pt) 2003-10-31
SE9703375D0 (sv) 1997-09-18
DK1014985T3 (da) 2003-09-15
NO20001399D0 (no) 2000-03-17
TW589183B (en) 2004-06-01
HUP0200602A2 (hu) 2002-07-29
EP1014985A1 (en) 2000-07-05
EE200000141A (et) 2001-02-15
HUP0200602A3 (en) 2003-04-28
AR015448A1 (es) 2001-05-02
ES2200370T3 (es) 2004-03-01
EP1014985B1 (en) 2003-05-21
DE69814882T2 (de) 2004-05-19
NO20001399L (no) 2000-05-10
US6159971A (en) 2000-12-12
CN1278729A (zh) 2001-01-03
ZA987817B (en) 1999-03-18
CA2302382A1 (en) 1999-03-25
NZ503171A (en) 2002-02-01
ATE240733T1 (de) 2003-06-15
MY116280A (en) 2003-12-31
IL134776A0 (en) 2001-04-30
TR200000727T2 (tr) 2000-09-21
JP2001516718A (ja) 2001-10-02
CN1195519C (zh) 2005-04-06
PL339371A1 (en) 2000-12-18
BR9812088A (pt) 2000-09-26
SK2852000A3 (en) 2000-09-12
RU2214824C2 (ru) 2003-10-27
AU9193098A (en) 1999-04-05
KR20010024076A (ko) 2001-03-26
WO1999013877A1 (en) 1999-03-25
HK1032739A1 (en) 2001-08-03
IS5406A (is) 2000-03-15
AU752722B2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
FI981132L (fi) Palvelun luvattoman käytön estäminen
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
NO993848L (no) FremgangsmÕte for bestemmelse av oljeegenskaper
DE60003148D1 (de) Bestimmung der Cachezeit
EP1289526A4 (en) MELANOCORTIN RECEPTOR AGONISTS
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
ID27574A (id) Inhibitor enzim
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
EE200000146A (et) Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
EE9700245A (et) 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
EE200100014A (et) Antidepressiivse toimega vahend
NO20005826D0 (no) Bionedbrytbare korrosjonsinhibitorer
NO994106L (no) Oksazolidiner som 5-HT2A-antagonister
EP1023068A4 (en) ALPHA 1a ADRENORE RECEPTOR ANTAGONISTS
DK1146874T3 (da) Vitronectinreceptoragonist
DE69903319D1 (de) Fkbp inhibitoren
EP1014973A4 (en) ALPHA-1a ADRENOR RECEPTOR ANTAGONISTS
EE04142B1 (et) Selektiivse 5-HT 1A antagonisti kombinatsioon selektiivse h5-HT 1B antagonisti või osalise agonistiga
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
SI1237553T1 (sl) Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
FI991343L (fi) Dihydropolyprenolien öljykoostumus
SI1014985T1 (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20050909